• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Latest News

Wegovy Demonstrates Superiority Over Placebo in Patients with Metabolic Dysfunction-Associated Steatohepatitis
Wegovy Demonstrates Superiority Over Placebo in Patients with Metabolic Dysfunction-Associated Steatohepatitis

November 1st 2024

Results from Part I of the Phase III ESSENCE trial found that Wegovy 2.4 mg achieved a 37% improvement in liver fibrosis without worsening steatohepatitis in patients with metabolic dysfunction-associated steatohepatitis compared to 22.5% in the placebo group.

Eisai Completes Rolling Biologics License Application to FDA for Subcutaneous Maintenance Dosing Option of Leqembi for Alzheimer Disease
Eisai Completes Rolling Biologics License Application to FDA for Subcutaneous Maintenance Dosing Option of Leqembi for Alzheimer Disease

November 1st 2024

Biopharma Needs a Health System Strategy to Secure Optimal Market Access
Biopharma Needs a Health System Strategy to Secure Optimal Market Access

November 1st 2024

Key Benefits of RWD in Privacy and Targeting Effectiveness
Key Benefits of RWD in Privacy and Targeting Effectiveness

November 1st 2024

‘Selling a Vision’: Today’s Playbook for Startups

The Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.

 The Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.

Conference Coverage

View All
The Impact of Artificial Intelligence on the Creation of Medicines
The Impact of Artificial Intelligence on the Creation of Medicines

October 24th 2024

Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?

October 23rd 2024

Sarclisa Combination Improves Progression-Free Survival in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma
Sarclisa Combination Improves Progression-Free Survival in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma

June 4th 2024

Moderna, Merck Present Promising Trial Data for a Combination of V940 with Keytruda for the Treatment of High-Risk Melanoma Following Complete Resection
Moderna, Merck Present Promising Trial Data for a Combination of V940 with Keytruda for the Treatment of High-Risk Melanoma Following Complete Resection

June 4th 2024

Latest Videos
Podcasts

All News